ATEROMA

REFERENCIAS BIBLIOGRÁFICAS 1. Jennifer G. Robinson JG, Williams KJ, Gidding S et al. Eradi- cating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc. 2018;7:e009778. DOI: 10.1161/JAHA.118.009778 2. Ference BA, Ginsberg HN, Graham I et al. Low-density lipopro- teins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consen- sus Panel. European Heart Journal 2017; 38 (32): 2459–2472 3. Dhindsa DS, Sandesara PB, Shapiro MD et al. Evolving Un- derstanding and Approach to Residual Cardiovascular Risk Management. Front. Cardiovasc. 2020; 7 (88); 1-11 https://doi. org/10.3389/fcvm.2020.00088 4. Raposeiras-Roubin S, Rosselló X, Oliva B et al Triglycerides and Residual Atherosclerotic Risk J Am Coll Cardiol 2021; 77(24): 3031-3041. 5. Castañer O, Pinto X, Subirana I et al Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Di- sease. J Am Coll Cardiol 2020 ; 76(23): 2712-2724. 6. Carrillo-Larco RM,Benites-Moya J, Anza-Ramirez C et al. A sys- tematic review of population-based studies on lipid profiles in Latin America and the Caribbean. eLife 2020; 9: e57980. DOI: https://doi.org/10.7554/eLife.57980 7. Millán Núñez-Cortés J, Pedro-Botet P, Brea-Hernando A et al. Consenso de expertos sobre propuestas para la mejora del ma- nejo de la dislipemia aterogénica. Rev Esp Cardiol 2014; 67(1): 36–44 8. Mach F, Baigent C, Catapano AL et al. Guidelines for the mana- gement of dyslipidaemias: lipid modification to reduce cardiovas- cular risk. European Heart Journal 2020; 41: 111-188 9. Arnett DK, Blumenthal RS et al 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Sum- mary. JACC 2019; 74(10): 1376 – 414 10.Grundy SM, Stone NJ, Bailey AL et al. Cholesterol Clinical Prac- tice Guidelines 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the Manage- ment of Blood Cholesterol. Circulation 2019; 139: e1082–e1143. DOI: 10.1161/CIR.0000000000000625 11.OPS 2021 (Junio 18). Nueva calculadora de riesgo cardiovascu- lar https://youtu.be/h8DPBVy7D-0. HEARTS www.paho.org/ es/ hearts-americas 12.Preiss D, Tobert JA, MD, Kees Hovingh G et al. Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors JACC Focus Seminar. J Am Coll Cardiol 2020; 75: 1945–55 13.Ulrich Laufs, Parhofer KG, Ginsberg HN et al. Clinical review on triglycerides. European Heart Journal 2020; 41: 99–109 14.Steven Driver SL, Martin SS, Gluckman J. Fasting or Nonfas- ting Lipid Measurements: It Depends on the Questio J Am Coll Cardiol 2016 ;67(10): 1227-1234 doi: 10.1016/j.jacc.2015.12.047 15.Virani SS, Morris PB et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Pa- tients With Persistent Hypertriglyceridemia. J Am Coll Card 2021; 78(9): 960–993 16.Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 2011; 32: 1345–1361 17.Jun M, Foote C, LyJ et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 2010; 375(9729): 1875-1884. doi: 10.1016/S0140-6736(10)60656-3 18.Maki KC, Guyton JR, Orringer CE et al. Triglyceride-lowering the- rapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. Journal of Clinical Lipidology 2016; 10(4): 905-914 19.Rohatgi A, Westerterp M, von Eckardstein A et al. HDL in the 21st Century AMultifunctional Roadmap for Future HDL Research Cir- culation 2021; 143: 2293-2309 20.Bhatt DL, Steg G, Miller M et al. Cardiovascular Risk Reduc- tion with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019; 380: 11-22. DOI: 10.1056/NEJMoa1812792 21.Ponte-Negretti CI, Wyss FS, Piskorz D, Santos RD, Vilar R, Lo- renzatti A, et al Consenso latinoamericano para el manejo del riesgo residual cardiometabolico. Consenso realizado por la Academia Latinoamericana de Lipidologia y Riesgo Cardiome- tabolico (ALALIP), con el aval de la Sociedad Interamericana de Cardiologia (SIAC), la Sociedad Internacional de Aterosclerosis (IAS) y el Colegio Panamericano de Endotelio (PACE). Arch Car- diol Mex (Eng) 2021 July (ahead of print) 83 ATEROMA - Resúmenes